83113-55-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-Tomoxetine (S)-(+)-mandelate is used as a therapeutic agent for the treatment of attention deficit hyperactivity disorder (ADHD). It acts on the neurotransmitter norepinephrine to increase its levels in the brain, which helps improve ADHD symptoms and overall patient well-being.
Used in Neurotransmitter Regulation:
(R)-Tomoxetine (S)-(+)-mandelate is used as a selective norepinephrine reuptake inhibitor to regulate the levels of norepinephrine in the brain. This regulation contributes to the amelioration of ADHD symptoms and the enhancement of cognitive functions in patients.
Used in Controlled Release Formulations:
(R)-Tomoxetine (S)-(+)-mandelate is used as a component in controlled release drug formulations, allowing for a sustained release of the medication. This extends the duration of action, reduces the need for frequent dosing, and improves patient compliance and treatment outcomes.

Upstream product

• 1027094-45-6 (R)-atomoxetine oxalate 
• 17199-29-0 (S)-Mandelic acid 
• 63940-51-2 (+/-)-atomoxetine 
• 107674-34-0 tomoxetine oxalic acid salt 
• 42142-52-9 3-methylamino-1-phenylpropan-1-ol 
• 95-52-3 2-Fluorotoluene 

Downstream Products

• 82248-59-7 atomoxetine hydrochloride 
• 63940-51-2 (+/-)-atomoxetine 
• 105314-52-1 (R)-tomoxetine 

Relevant academic research and scientific papers

"AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3- PHENYLPROPYLAMINE AND SALT THEREOF"

The present invention relates to an industrially feasible and economically viable process for the preparation of 3-aryloxy-3-phenylpropylamine and salt of formula (I) thereof.

AN IMPROVED PROCESS FOR SYNTHESIZING HIGHLY PURE ATOMOXETINE

The present invention relates to a process for the preparation of highly pure atomoxetine of formula (I) and pharmaceutically acceptable salts thereof Formula (I) The present invention also aims at novel processes for the preparation and purification of intermediates involved in the process of the present invention.

A PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE

Provided is the process for the preparation of Atomoxetine hydrochloride by the condensation of N,N-dimethyl 3-phenyl-3-chloropropyl amine acid addition salt with o- cresol in presence of a phase transfer catalyst and base followed by demethylation and resolution. Also provided preparation of crystalline Atomoxetine hydrochloride.

PROCESS FOR PREPARING ATOMOXETINE HYDROCHLORIDE

The present invention relates to the process for preparing Atomoxetine hydrochloride which is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is chemically known as (-)-iV-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride and represented by formula (I). More particularly, the invention relates to crystalline form of N-methyl-3-phenyl-3-(o- tolyloxy) propylamine oxalate (here in after referred as "(±) Atomoxetine Oxalate"), which is an useful intermediate for the synthesis of Atomoxetine hydrochloride.

SYNTHESIS OF ATOMOXETINE HYDROCHLORIDE

(±)-Atomoxetine oxalate having crystalline Form II and a solid (±)-atomoxetine free base are useful in preparing atomoxetine hydrochloride.

3-ARYLOXY-3-ARYLPROPYLAMINE SYNTHESIS

A process for preparing a 3-aryloxy-3-arylpropylamine comprises reacting a 3-hydroxy-3-arylpropylamine with a substituted aryl compound, in a solvent comprising N-N-dimethylacetamide or hexamethylphosphorous triamide.

Process for the preparation of atomoxetine hydrochloride

The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water.